NASDAQ · Analyst Forecast

Rocket Pharmaceuticals, Inc. (RCKT) Stock Forecast & Price Target

$2.11 NASDAQ: RCKT Market Cap $235.60M

Price as of Nov 18, 2026 close · Analyst estimates retrieved Nov 18, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)

Revenue and earnings estimates published by analysts covering Rocket Pharmaceuticals, Inc. (RCKT), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For Rocket Pharmaceuticals, Inc., analysts forecast revenue rising from $454,545 in 2025 to $203.82M in 2030; the average estimate for 2030 earnings per share is −$0.27; with published estimates ranging from −$0.44 to −$0.07; 9 analysts contribute to these figures. These are forecasts published by analysts, not results.

Analyst price targets

MeasureValue
Current priceWhat the share trades at now.$2.11
Consensus targetThe average of the price targets analysts have published.$5.32
Median targetThe middle target, less affected by a single outlier.$4.00
Highest targetThe most optimistic published target.$9.00
Lowest targetThe most pessimistic published target.$2.95
Difference from priceHow far the consensus target sits from today’s price.+152.1%

A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.

Revenue forecast (USD)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

YearLowAverageHighAnalysts
2025$102,321$454,545$888,6259
2026$476,185$1.11M$1.67M6
2027$3.14M$11.27M$18.50M8
2028$6.09M$14.16M$21.33M8
2029$29.35M$68.25M$102.84M6
2030$87.65M$203.82M$307.13M6

Earnings per share forecast

YearLowAverageHighAnalysts
2025−$2.16−$2.05−$1.999
2026−$0.21−$0.15−$0.046
2027−$1.84−$1.50−$1.028
2028−$1.55−$1.14−$0.728
2029−$1.47−$0.88−$0.236
2030−$0.44−$0.27−$0.076

Rocket Pharmaceuticals, Inc. (RCKT) forecast — frequently asked questions

What is the analyst price target for Rocket Pharmaceuticals, Inc.?

Analysts covering Rocket Pharmaceuticals, Inc. (RCKT) have a consensus price target of $5.32, 152.1% above the current price of $2.11. Published targets range from $2.95 to $9.00. A price target is a forecast, not a measure of value, and targets are revised often.

What are analysts forecasting for Rocket Pharmaceuticals, Inc.'s earnings?

The average analyst estimate for Rocket Pharmaceuticals, Inc. (RCKT) earnings per share in 2030 is -0.27, with individual estimates between -0.44 and -0.07.

How much revenue is Rocket Pharmaceuticals, Inc. expected to make?

Analysts forecast Rocket Pharmaceuticals, Inc. (RCKT) revenue of $203.82M in 2030, based on 6 published estimates.

How many analysts cover RCKT?

9 analysts contribute estimates for Rocket Pharmaceuticals, Inc. (RCKT). Thin coverage makes an average less reliable.

Analyst forecasts for other Biotechnology stocks

VRTX forecastREGN forecastMRNA forecastRVMD forecastROIV forecastINSM forecastUTHR forecastINCY forecastALNY forecastASND forecastAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.